TrialHaematologica2024

Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.

Karthik Ramasamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.